Organogenesis (NASDAQ:ORGO) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Organogenesis (NASDAQ:ORGO) released its earnings results on Tuesday. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11, Zacks reports. The company had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the previous year, the business posted $0.02 EPS. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Stock Performance

NASDAQ:ORGO traded down $0.20 during trading hours on Friday, reaching $3.81. The stock had a trading volume of 147,065 shares, compared to its average volume of 822,741. The stock has a 50 day simple moving average of $2.97 and a 200 day simple moving average of $2.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.42 and a current ratio of 3.09. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.70.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.